John Carpenter’s Post

𝐓𝐡𝐞𝐫𝐚𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 - $4.3 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028 Download PDF Brochure @ https://lnkd.in/ddsm9Be4 The global 𝐭𝐡𝐞𝐫𝐚𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧 𝐭𝐞𝐫𝐦𝐬 𝐨𝐟 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐰𝐚𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐰𝐨𝐫𝐭𝐡 $2.1 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2023 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $4.3 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 15.5% from 2023 to 2028 Key market players are adopting various growth strategies to strengthen their foothold in this region. For instance, in August 2019, Eckert & Ziegler (Germany) initiated a joint venture with Chengdu New Radiomedicine Technology Co., Ltd. (China) to set up a new production facility for radiopharmaceuticals used in the treatment of hepatocellular carcinomas in China. According to an article published in the European Journal of Nuclear Medicine and Molecular Imaging 2022, by 2025, about 50 new centralized radiopharmacies will be built across China, and the availability and accessibility of radiopharmaceuticals will be significantly improved by then. Advanced Accelerator Applications , Bayer | Pharmaceuticals, GE HealthCare 𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬

SFBN Feed: GE HealthCare to take over Japanese radiopharmaceutical venture https://lnkd.in/gEgMJS2m GE HealthCare plans to take full control of Nihon Medi-Physics, makers of diagnostic radiopharmaceuticals and molecular imaging agents. The company had previously split ownership of the Tokyo-based nuclear medicine outfit down the middle with Sumitomo [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

🚀 A New Breakthrough in Drug Development: Elucidating Chiral Structures with NMR Spectroscopy Researchers from the Karlsruhe Institute of Technology (KIT) and Voxalytic GmbH have made an exciting advancement in nuclear magnetic resonance (NMR) spectroscopy, allowing for the first-time direct measurement of molecular chirality. This development could revolutionize drug discovery, as understanding a molecule’s chiral structure is crucial for ensuring its safety and effectiveness in pharmaceuticals. The ability to determine whether a molecule is left-handed or right-handed, known as its chirality, plays a critical role in biochemical reactions. History reminds us how devastating mistakes in chirality can be—the case of Thalidomide, which led to birth defects in the 1960s, underscores the importance of this discovery. This newly patented method, developed under the leadership of Professor Jan Korvink at KIT, is expected to become a standard tool in the pharmaceutical industry, potentially accelerating drug screening and the search for safe, effective active ingredients. What does this mean for the future of drug development? This innovation could drastically cut down the time it takes to develop new drugs by offering a precise, atomic-level view of molecular structures. #PharmaceuticalInnovation #DrugDevelopment #Chirality #NMRspectroscopy #ChemicalResearch #Enantiomers #AdvancedMaterials #MolecularStructure #BiotechBreakthrough #KarlsruheInstituteOfTechnology #KIT #NIT #IIT #Voxalytic #HealthcareInnovation #DrugChemistry #MedicinalChemistry #Biotechnology #MolecularBiology #Nanotechnology #StemCellResearch #DrugDiscovery #Pharmacology #Biopharmaceuticals #StructuralBiology #DrugScreening #Chemistry #OrganicChemistry #AnalyticalChemistry

Pepticom designs (and not randomly designs) highly stable peptide drug that can remain active in the body for longer periods, increasing their bioavailability. With AI algorithms and reinforcement learning backed by laboratory synthesis, Pepticom can discover the most effective peptide sequences for specific targets, in expedited process and timeline. We are excited to be part of your journey to revolutionize peptide development with unprecedented efficiency and precision and scalability.

𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐫𝐞𝐭𝐫𝐨-𝐢𝐧𝐯𝐞𝐫𝐬𝐨 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐚𝐧𝐝 𝐭𝐡𝐞𝐢𝐫 𝐫𝐨𝐥𝐞 𝐢𝐧 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲? Peptide drugs, though often potent in their biological activities, often face hurdles such as protease degradation that reduces their half life and bioavailability. However, retro-inverso #peptides, a kind of non canonical peptides recently explored in a new article on #drugdiscovery, are a promising solution for drug developers. Retro-inverso peptides are a type of peptidomimetic using D-amino acids (retro isomers) and inverting the primary sequence of the original peptide (inverted). This dual modification creates a stable version of the peptide that is not easily recognized and broken down by biological systems. As retro-inverso peptides are more resistant to proteolytic degradation they can remain active in the body for longer periods increasing their bioavailabiity, while their unique structure can enhance binding affinity and specificity to their targets. This makes them highly interesting in drug discovery. Yet their implementation can be intricate and time-consuming. Fortunately, artificial intelligence can facilitate and expedite the process, revolutionizing peptide development. AI algorithms can analyze vast datasets of peptide sequences and structure-function relationships to design the most effective peptide sequences for specific targets, with enhanced peptide durability and absorption in the body. For example, by leveraging machine learning techniques, researchers can design shorter versions of retro-inverso peptides with optimized biological properties. AI-enabled virtual screening platforms can also expedite the selection of retro-inverso peptidomimetics for experimental validation. By predicting binding affinities and interactions with target receptors, AI algorithms narrow down the pool of candidates, streamlining the selection process and reducing the need for extensive experimental testing. Last but not least, AI algorithms can optimize experimental design and data analysis for phage binding assays, accelerating the identification of retro-inverso peptidomimetics that effectively compete with native peptides for receptor binding. Machine learning models can analyze assay results in real-time, guiding researchers towards promising candidates for further characterization. Integrating AI into the retroinversion pipeline, it is clear, will revolutionize peptidomimetic development and provide unprecedented efficiency and precision, and scalability. Read the full article on peptidomimetic development here >> https://lnkd.in/d9ykxYj8 #AI

NMR Coupled with Multivariate Data Analysis for Monitoring the Degradation of a Formulated Therapeutic Monoclonal Antibody The function of a protein is directly coupled to its higher-order structure (HOS). Deviations in this critical quality attribute (CQA) may be linked to a decrease in the efficacy and/or safety of the final therapeutic product. High-resolution nuclear magnetic resonance (NMR) spectroscopy has been recently highlighted for protein HOS characterization, thanks to its ability to capture small changes at the molecular and structural levels (primary, secondary, tertiary and quaternary). The present study was carried out to demonstrate the ability of NMR (1D 1H and 2D 1H-13C experiments) coupled with multivariate data analysis (PCA and PLS regression) to monitor the degradation of a formulated mAb-like protein and for the simultaneous quantification of related CQAs, i.e., potency, purity and impurities (aggregates and fragments). The results indicate that this approach could be applied to mitigate product quality risks during development, manufacturing and stability studies of mAb therapeutics. https://lnkd.in/gZhF6uwm #aspenalert #biotech #bioprocess

Orbit Discovery and Evergreen Theragnostics have extended their research collaboration to develop novel targeting peptides for radiopharmaceutical delivery. This partnership builds on a previous agreement and combines Orbit's peptide discovery platform with Evergreen's expertise in radiopharmaceuticals

Today we celebrate our new partnership with Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of advancing a small molecule condensate modulator (#cmod) that corrects an underlying pathology shared by ~97 % of all ALS patients: the mislocalization of the TDP-43 splicing factor into aberrant cytoplasmic condensates. Our expertise in #condensate science will complement MTPC’s unrivaled expertise in ALS drug development to progress a c-mod discovered in house using our proprietary platform. 🔬 The c-mod selectively restores nuclear localization of TDP-43, promotes neuronal health in in vitro pre-clinical models, and demonstrated improvement of multiple ALS biomarkers in in vitro and in vivo preclinical models.  Read more about the science and financial details of this exciting new milestone here: https://lnkd.in/ghWguxv5  

𝗧𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁𝗲𝗱 𝘁𝗼 𝗪𝗼𝗿𝘁𝗵 $4.3 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 2028 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲-https://lnkd.in/dPYYBcnK The global theranostics market in terms of revenue was estimated to be worth $2.1 Billion in 2023 and is poised to reach $4.3 Billion by 2028, growing at a CAGR of 15.5% from 2023 to 2028. 𝐌𝐚𝐢𝐧 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Advanced Accelerator Applications Bayer GE HealthCare Siemens Healthineers Cardinal Health Philips Canon Inc. Curium Pharma Lantheus NorthStar Medical Radioisotopes, LLC Eckert & Ziegler SE Pharmalogic Eczacıbaşı-Monrol Nuclear Products Acrotech Biopharma, INC Thermo Fisher Scientific Global Medical Solutions SHINE Technologies Isotopia Molecular Imaging ltd Institute of Isotopes Co. Ltd. China Isotope & Radiation Corp Yantai Dongcheng Pharmaceutical Group Co., Ltd AtomVie Global Radiopharma Inc. ABX advanced biochemical compounds GmbH Telix Pharmaceuticals Limited Blue Earth Diagnostics Sofie Biosciences, Inc. Theragnostics

Australia is poised to take center stage in the global radiopharmaceutical industry 🌏, according to a new discussion paper by MTPConnect. This exciting development comes as advanced therapies continue to attract significant investment and fuel rapid expansion. Radiopharmaceuticals are cutting-edge nuclear medicines that are used for both medical imaging and treatment ☢️. These powerful drugs are designed to target specific organs or tissues, enabling doctors to accurately diagnose and administer targeted therapies for diseases like cancer. Titled 'From Mines to Medicines: Australia's Radiopharmaceuticals Future,' the discussion paper sheds light on Australia's unique advantages over the rest of the world. It all starts with our abundant mining assets and the valuable waste products they yield, particularly in South Australia. The paper outlines a comprehensive national roadmap that aims to capitalize on this opportunity and harness our competitive edge. 🥇 With Australia's rich resources and strategic vision, we are well-positioned to lead the way in the global radiopharmaceutical industry. This exciting prospect not only promises significant advancements in medical imaging and treatment but also opens up new avenues for investment and economic growth 📈. Let's embrace this opportunity and pave the way for a brighter future in healthcare 🏥. https://lnkd.in/gNG4mJ7f https://lnkd.in/emixWg46 #Nuclear #Medicine #Healthcare #Radiopharmaceutical #SouthAustralia #Future #Opportunity #Fusion #Auspol